Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NC 318

Next Previous
Drug Profile

NC 318

Alternative Names: NC-318

Latest Information Update: 09 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University School of Medicine
  • Developer Emory University; Merck Sharp & Dohme; National Cancer Institute (USA); NextCure; Yale University School of Medicine
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Leukaemia; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 09 May 2024 NC 318 is available for licensing as of 08 May 2024. https://www.sec.gov/ix?doc=/Archives/edgar/data/1661059/000155837024003672/nxtc-20231231x10k.htm
  • 12 Sep 2023 Efficacy and adverse event data from phase II trial in Non-small cell lung cancer released by NextCure
  • 09 Sep 2023 Updated Efficacy data from a phase II trial in Non-small cell lung cancer presented at the 24th World Conference on Lung Cancer, 2023 (WCLC-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top